A number of firms have modified their ratings and price targets on shares of athenahealth (NASDAQ: ATHN) recently:

  • 8/2/2017 – athenahealth had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $170.00 price target on the stock, up previously from $150.00.
  • 8/2/2017 – athenahealth had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $125.00 price target on the stock, up previously from $108.00.
  • 8/1/2017 – athenahealth was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/31/2017 – athenahealth was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating. They now have a $133.00 price target on the stock, up previously from $127.00.
  • 7/24/2017 – athenahealth was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/24/2017 – athenahealth had its “positive” rating reaffirmed by analysts at Leerink Swann. They now have a $155.00 price target on the stock, up previously from $140.00.
  • 7/24/2017 – athenahealth was downgraded by analysts at First Analysis from an “equal weight” rating to an “underweight” rating. They now have a $125.00 price target on the stock, up previously from $99.00.
  • 7/24/2017 – athenahealth had its “positive” rating reaffirmed by analysts at UBS AG. They now have a $175.00 price target on the stock, up previously from $157.00.
  • 7/24/2017 – athenahealth had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $186.00 price target on the stock, up previously from $169.00.
  • 7/22/2017 – athenahealth had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $163.00 price target on the stock, up previously from $155.00.
  • 7/22/2017 – athenahealth had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $190.00 price target on the stock, up previously from $130.00.
  • 7/21/2017 – athenahealth had its “market perform” rating reaffirmed by analysts at William Blair.
  • 7/21/2017 – athenahealth had its “overweight” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $171.00 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 7/21/2017 – athenahealth had its price target raised by analysts at Oppenheimer Holdings, Inc. from $154.00 to $184.00. They now have an “outperform” rating on the stock.
  • 7/20/2017 – athenahealth was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
  • 7/19/2017 – athenahealth was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 7/19/2017 – athenahealth was given a new $136.00 price target on by analysts at J P Morgan Chase & Co. They now have a “hold” rating on the stock.
  • 7/17/2017 – athenahealth had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $150.00 price target on the stock.
  • 7/14/2017 – athenahealth had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $152.00 price target on the stock.
  • 7/12/2017 – athenahealth was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/10/2017 – athenahealth had its “buy” rating reaffirmed by analysts at Citigroup Inc.. They now have a $169.00 price target on the stock, up previously from $163.00.
  • 7/7/2017 – athenahealth was downgraded by analysts at Dougherty & Co from a “buy” rating to a “neutral” rating.
  • 7/7/2017 – athenahealth is now covered by analysts at Argus. They set a “hold” rating on the stock.
  • 7/4/2017 – athenahealth was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/26/2017 – athenahealth had its “hold” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $135.00 price target on the stock.
  • 6/24/2017 – athenahealth was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/16/2017 – athenahealth had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $151.00 price target on the stock, up previously from $106.00.
  • 6/13/2017 – athenahealth was downgraded by analysts at Cantor Fitzgerald from an “overweight” rating to a “neutral” rating. They now have a $140.00 price target on the stock. They wrote, “It is difficult to predict what the ultimate outcome will be given the Elliott stake. Over the years, ATHN has typically invested for longer-term growth, which has often resulted in inconsistent quarterly performance. After a bumpy roll-out of the streamlined platform last year, we believe performance has improved. Also, the company’s investment in the small hospital market is moving along better than we originally expected. We maintain our view that the company can help physician offices transition to value-based reimbursement and increase its population health offerings. It remains to be seen if athena can enhance the functionality of its hospital offering to move into larger hospitals. Still, athena continues to have a significant presence in the ambulatory market, and it should be able to better leverage its capabilities over time. Praxify Techologies acquisition reflects another long-term investment. On June 7, ATHN announced that it acquired privately-held Praxify Technologies for $63 million in cash. We characterize this acquisition as a technology acquisition which should help the company add app-layer technology to its ambulatory and inpatient products. We assume the acquisition will be dilutive in the near term but help the company’s long-term product performance. Basis for higher price target. With the filing by Elliott, we increased our DCF-based price target to $140.””

Shares of athenahealth, Inc. (NASDAQ:ATHN) opened at 141.45 on Monday. The firm’s 50-day moving average is $143.27 and its 200-day moving average is $124.42. The firm has a market capitalization of $5.65 billion, a price-to-earnings ratio of 179.51 and a beta of 1.77. athenahealth, Inc. has a 12-month low of $90.11 and a 12-month high of $158.66.

athenahealth (NASDAQ:ATHN) last announced its quarterly earnings results on Thursday, July 20th. The health services provider reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.12. The firm had revenue of $301.10 million for the quarter, compared to analysts’ expectations of $298.68 million. athenahealth had a net margin of 2.80% and a return on equity of 6.91%. athenahealth’s revenue was up 15.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.34 earnings per share. Equities research analysts forecast that athenahealth, Inc. will post $1.91 EPS for the current fiscal year.

In other athenahealth news, SVP Bradford Kyle Armbrester sold 2,431 shares of athenahealth stock in a transaction that occurred on Thursday, May 18th. The shares were sold at an average price of $130.00, for a total transaction of $316,030.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Jonathan D. Porter sold 300 shares of athenahealth stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $109.48, for a total transaction of $32,844.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 22,905 shares of company stock worth $3,120,107. 3.20% of the stock is currently owned by corporate insiders.

athenahealth, Inc provides network-based medical record, revenue cycle, patient engagement, care coordination and population health services. The Company also offers Epocrates and other point-of-care mobile applications. The Company delivers majority of its service offerings through a single instance of cloud-based software, athenaNet.

Receive News & Ratings for athenahealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for athenahealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.